Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction

Lancet

Volumn 348, Issue 9019, 1996, Pages 7-12

  Waldo, Albert L ^a,h   Camm, A John ^b   DeRuyter, Hans ^c   Friedman, Peter L ^d   MacNeil, Daniel J ^c   Pauls, John F ^c   Pitt, Bertram ^e   Pratt, Craig M ^f   Schwartz, Peter J ^g   Veltri, Enrico P ^c  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c BRISTOL MYERS SQUIBB   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF MICHIGAN   (United States)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

^g UNIVERSITY OF PAVIA   (Italy)

^h UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

POTASSIUM CHANNEL BLOCKING AGENT; SOTALOL;

ADULT; AGED; ARTICLE; CAUSE OF DEATH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HEART ARRHYTHMIA; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 8944234858     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)02149-6     Document Type: Article

References (43)

1. Myerburg RJ, Kessler KM, Castellanos A Sudden cardiac death: structure, function and time dependence. Circulation. 85(suppl I):1992;2-10.
2. Mukharji J, Rude RE, Poole WKet al. Risk factors for sudden death after acute myocardial infarction: 2 year follow-up. Am J Cardiol. 54:1984;31-36.
3. Moss AJ, Davis HT, DeCamilla J, Bayer LW Ventricular ectopic beats and their relation to sudden and nonsudden cardiac death after myocardial infarction. Circulation. 60:1978;998-1003.
4. Steinberg J, Regan A, Sciacca R, Bigger JT Jr., Fleiss J Predicting arrhythmic events after acute MI using the signal-averaged electrocardiogram. Am J Cardiol. 69:1992;13-21.
5. Odemuyiwa O, Malik M, Farrell TG, Bashir Y, Poloniecki J, Camm AJ. Comparison of the predictive characteristics of heart rate variability index and left ventricular ejection fraction for all-cause mortality, arrhythmic events and sudden death after acute myocardial infarction. Am J Cardiol 1991; 68: 434-39.
6. Schwartz PJ, La Rovere MT, Vanoli E Autonomic nervous system and sudden cardiac death. Circulation. 85(suppl I):1992;78-91.
7. SOLVD Investigators Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 325:1991;293-302.
8. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985; 27: 335-71.
9. The Cardiac Arrhythmias Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989; 321: 406-12.
10. Schwartz PJ, Camm AJ, Frangin G, Janse MJ, Julian DG, Simon P, on behalf of the EMAIT Investigators. Does amiodarone reduce sudden death and cardiac mortality after myocardial infarction? Eur Heart J 1994; 15: 620-24.
11. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. N Engl J Med 1991; 324: 781-88.
12. The Cardiac Arrhythmia Suppression Trial II Investigators. Effect of antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 1992; 327: 227-33.
13. Teo KK, Yusuf S, Furberg CD. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction: an overview of results from randomized control trials. JAMA 1993; 270: 1589-95.
14. Burkart F, Pfisterer M, Kiowski W, Follath F, Burckhardt D. Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS). J Am Coll Cardiol 1990; 16: 1711-18.
15. Ceremuzynski Y, Kleczar E, Krzeminska-Pakula M, et al. Effect of amiodarone on mortality after myocardial infarction: a double-blind, placebo-controlled, pilot study. J Am Coll Cardiol 1992; 20: 1056-62.
16. Singh SN, Fletcher RD, Gross-Fisher Set al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med. 333:1995;77-82.
17. Doval HC, Nul DR, Grancelli HO, Perrone SV, Bortman GR, Curiel R, for Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). Randomised trial of low-dose amiodarone in severe congestive heart failure. Lancet 1994; 344: 493-98.
18. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. The Silican Gambit: a new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Circulation 1991; 84: 1831-51 and Eur Heart J 1991; 12: 1112-31.
19. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. The Silican Gambit: a new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Circulation 1991; 84: 1831-51 and Eur Heart J 1991; 12: 1112-31.
20. Kato R, Ikeda N, Yabek S, Ramswamy K, Singh B. Electrophysiologic effects of the levo- and dextrorotatory isomers of sotalol in isolated cardiac muscle and their in vivo pharmacokinetics. J Am Coll Cardiol 1986; 7: 116-25.
21. Gomoll AW, Bartek MJ. Comparative β-blocking activities and electrophysiologic actions of racemic sotalol and its optical isomers in anesthetized dogs. Eur J Pharmacol 1986; 132: 123-35.
22. Johnston GD, Finch MB, McNeill JA, Shanks RG. A comparison of the cardiovascular effects of (+)-sotalol and (±)-sotalol following intravenous administration in normal volunteers. Br J Clin Pharmacol 1985; 20: 507-10.
23. Lynch JJ, Coskey LA, Montgomery DG, Lucchesi BR. Prevention of ventricular fibrillation by dextrorotatory sotalol in a conscious canine model of sudden coronary death. Am Heart J 1985 109: 949-58.
24. Vanoli E, Hull SS Jr, Adamson PB, Schwartz PJ. Effect of d-sotalol on ventricular fibrillation in conscious dogs with a healed myocardial infarction. Eur Heart J 1993; 14 (suppl): 92 (abstr).
25. Waldo AL, Camm AJ, DeRuyter H, et al. The SWORD trial. Survival with oral d-sotalol in patients with left ventricular dysfunction after myocardial infarction: rationale. design and methods. Am J Cardiol 1995; 75: 1023-27.
26. Hinkle LE, Thaler HT. Clinical classification of cardiac deaths. Circulation 1982; 65: 457-64.
27. Greene HL, Richardson DW, Barker AHet al. Classification of deaths after myocardial infarction as arrhythmic or non-arrhythmic (The Cardiac Arrhythmia Pilot Study). Am J Cardiol. 63:1989;1-6.
28. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. The early termination of clinical trials: causes, consequences, and control: with special reference to trials in the field of arrhythmias and sudden death. Circulation 1994; 89: 2892-907.
29. Lan KG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika 1983; 70: 659-63.
30. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometric 1979; 35: 549-56.
31. DeMets DL. Practical aspects in data monitoring: a brief review. Stat Med 1987; 6: 753-60.
32. DeMets DL, Ware JH. Group sequential methods for clinical trials with a one-sided hypothesis Biometrika 1980; 67: 651-60.
33. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
34. Cox DR. Regression models and life-tables. J Roy Stat Soc Ser B 1972; 34: 1987-202.
35. Priori SG, Diehl L, Schwartz PJ. Torsade de Pointes. In: Podrid PJ, Kowey PR, eds. Cardiac arrhythmia: mechanisms, diagnosis, and management. Baltimore: Williams and Wilkins, 1995: 951-63.
36. Makkar RR, Fromm BS, Steinmann RT, Meissner MD, Lehmann MH. Female gender as a risk factor for torsade de pointes associated with cardiovascular drugs. JAMA 1993; 270: 2590-97.
37. Vanoli E, Hull SS Jr, Adamson PB, Foreman RD, Schwartz PJ. K+ channel blockade in the prevention of ventricular fibrillation due to acute ischemia and enhanced sympathetic activity. J Cardiovasc Pharmacol 1995; 26: 847-54.
38. Kr blockade: implications for the antifibrillatory efficacy of K+ channel blockers. J Am Coll Cardiol 1995; 25: 1609-14.
39. Malliani A, Schwartz PJ, Zanchetti A. A sympathetic reflex elicited by experimental coronary occlusion. Am J Physiol 1969; 217: 703-07.
40. Sanguinetti MC, Jurkiewicz NK Two components of cardiac delayed rectifier K+ current differential sensitivity to block by class III antiarrhythmic agents. J Gen Physiol. 96:1990;195-215.
41. Pfeffer M, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992; 327: 669-77.
42. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327: 685-91.
43. Podrid PJ, Lampert S, Grayboys TB, Blatt CM, Lown B Aggravation of arrhythmia by antiarrhythmic drugs: incidence and predictors. Am J Cardiol. 59:1987;38E-44E.